Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints
On Tuesday, Sanofi SA (NASDAQ: SNY ) reported data from the Phase 3 Baby-COMET study of Nexviazyme (avalglucosidase alfa). Read Also: EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims Phase 3 Trial Hits Primary And Secondary Endpoints The trial showed that Nexviazyme met its primary e